Citations (8)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Christian Klein, Candice Jamois & Tina Nielsen. (2021) Anti-CD20 treatment for B-cell malignancies: current status and future directions. Expert Opinion on Biological Therapy 21:2, pages 161-181.
Read now
Read now
Ramona Wullenkord, Birte Friedrichs, Tabea Erdmann & Georg Lenz. (2019) Therapeutic potential of PI3K signaling in distinct entities of B-cell lymphoma. Expert Review of Hematology 12:12, pages 1053-1062.
Read now
Read now
Christian Klein, Marina Bacac, Pablo Umana & Günter Fingerle-Rowson. (2017) Combination therapy with the type II anti-CD20 antibody obinutuzumab. Expert Opinion on Investigational Drugs 26:10, pages 1145-1162.
Read now
Read now
Jacqueline C Barrientos. (2016) Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential. OncoTargets and Therapy 9, pages 2945-2953.
Read now
Read now
Serena Kimi Perna, Leslie E Huye & Barbara Savoldo. (2015) Management of patients with non-Hodgkin’s lymphoma: focus on adoptive T-cell therapy. ImmunoTargets and Therapy 4, pages 55-63.
Read now
Read now
Mengjiao Sun, Jun Wang, Qin Lu, Guohua Xia, Yu Zhang, Lina Song & Yongjun Fang. (2015) Novel synthesizing method of pH-dependent doxorubicin-loaded anti-CD22-labelled drug delivery nanosystem. Drug Design, Development and Therapy 9, pages 5123-5133.
Read now
Read now
Andrew Davies. (2015) Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin’s lymphoma: an overview of pharmacokinetics and clinical trial outcomes. Expert Review of Hematology 8:5, pages 581-593.
Read now
Read now
Ruth Pettengell & Jasvinder Kaur. (2015) Pixantrone dimaleate for treating non-Hodgkin’s lymphoma. Expert Opinion on Orphan Drugs 3:6, pages 747-757.
Read now
Read now